A Phase 3, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study of NRP104 in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008258/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study is designed to assess efficacy and safety of NRP-104 administered as a daily dose
of 30mg, 50mg or 70mg compared to placebo in the treatment of children aged 6-12 years with
ADHD.
提供机构：
Vivli
创建时间：
2022-07-15
